The commutability of enzyme linked immunosorbent assays for the quantification of serum eosinophil-derived neurotoxin (EDN).
EDN
ELISA
Eosinophil-derived neurotoxin
Validation
Journal
Journal of immunological methods
ISSN: 1872-7905
Titre abrégé: J Immunol Methods
Pays: Netherlands
ID NLM: 1305440
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
22
08
2021
revised:
28
10
2021
accepted:
03
11
2021
pubmed:
12
11
2021
medline:
7
1
2022
entrez:
11
11
2021
Statut:
ppublish
Résumé
Eosinophil-derived neurotoxin (EDN) is a surrogate biomarker of eosinophil activation and has considerable potential as a precision medicine biomarker in diseases where eosinophils may play a causative role. Clinical data for EDN have been generated using different quantitative immunoassays, but comparisons between these individual data sets are challenging as no internationally recognised EDN standards or orthogonal methods exist. In this study we aimed to compare commercial EDN assays from ALPCO, MBL, LSBio and CUSABIO for sample commutability. Firstly, we analytically validated the ALPCO enzyme linked immunosorbent assay (ELISA) and demonstrated appropriate analytical characteristics, including an intra/inter-assay precision coefficient-of-variation of between 1.9 and 6.8%. EDN purified from blood proved to be a good quality control material, whereas recombinant EDN, expressed in E.coli, did not react in the ALPCO immunoassay. Using healthy and asthma patient serum samples we confirmed that the ALPCO assay correlated well with the MBL assay, with a coefficient of determination (R
Identifiants
pubmed: 34762913
pii: S0022-1759(21)00226-X
doi: 10.1016/j.jim.2021.113181
pii:
doi:
Substances chimiques
Biomarkers
0
Eosinophil-Derived Neurotoxin
EC 3.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
113181Informations de copyright
Copyright © 2021. Published by Elsevier B.V.